Fosun plans to raise nearly $5 billion to focus on the development of innovative drugs such as the new crown vaccine

On November 25, 2020, Fosun Pharma announced plans to issue A-shares in a non-public offering, with a total investment of 2.2 billion yuan in drug innovation.
announced that the non-public issue of A-shares for no more than 35 specific investors, non-public issuance of A-shares to raise funds not more than 498,283 million yuan (including this amount), net of the issuance costs will be used for innovative drug research and development, licensing and the introduction and construction of raw materials and preparations intensive integrated base.
funding is as follows: As an innovative pharmaceutical company, Fosun Pharma continues to increase its code in the field of innovative pharmaceutical research and development.
understand that from 2013 to 2019, Fosun Pharma's research and development investment increased from 505 million to 3.463 billion yuan, with a cumulative investment of 10.625 billion yuan in research and development in the past seven years.
research and development expenses in the first three quarters of 2020 were 1,878 million yuan, an increase of 45.55 percent over the same period in 2019.
and the funds raised by this non-public offering of shares, Fosun will invest 2.2 billion yuan in clinical development of innovative drugs, commercial licensing, licensing of the introduction of project research and development milestones and some product launch preparation related follow-up costs.
specific research and development direction and corresponding investment estimates are as follows: After the outbreak of the new crown, Fosun Pharma is also involved in the vaccine research and development process.
2020, Fosun Pharma and BioNTech reached a cooperation agreement to invest $135 million in the development of the new crown vaccine.
August 2020, Fosun Pharma and BioNTech jointly announced that nearly 100 subjects had been vaccinated against BNT162b1 after the new coronavirus mRNA vaccine (BNT162b1) was approved for clinical trials by the National Drug Administration.
November 13, Fosun Pharma received clinical trial approval from the State Drug Administration for its approved new coronavirus mRNA vaccine BNT162b2 for the prevention of new coronavirus pneumonia, and officially launched phase II clinical trials of the vaccine in China (excluding Hong Kong, Macao and Taiwan).
of the 220 million yuan of innovative drug research and development funds, Fosun will invest 324 million yuan in the new coronavirus mRNA vaccine to promote the BNT162b2 vaccine in Chinese mainland Phase II clinical trials, as well as GSP storage, cold chain logistics and other relevant preparations for the listing.
。